IL4R and chronic obstructive pulmonary disease: For instance, eosinophilic COPD has been shown to be an important treatable trait, where administration of a monoclonal antibody against the interleukin-4 receptor leads to a clinically relevant reduction in the rate of COPD exacerbations in individuals with COPD and a high level of circulating eosinophils [29, 30].